How many drugs treat Chronic schizophrenia?

Drug Landscape tracks 3 marketed treatments for Chronic schizophrenia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chronic-schizophrenia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chronic schizophrenia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic schizophrenia (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic schizophrenia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Barhemsys	AMISULPRIDE	Acacia	Dopamine-2 Receptor Antagonist [EPC]	D(2) dopamine receptor	2020-01-01
Haldol	HALOPERIDOL DECANOATE	Johnson & Johnson	Typical Antipsychotic	D(2) dopamine receptor	1986-01-01
Haldol	haloperidol	Johnson & Johnson (Janssen)	Typical Antipsychotic [EPC]	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A	1967-04-12

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Chronic schizophrenia
Acacia · 1 drug in Chronic schizophrenia
Johnson & Johnson · 1 drug in Chronic schizophrenia
Johnson & Johnson (Janssen) · 1 drug in Chronic schizophrenia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic schizophrenia:

Cite this brief

Drug Landscape (2026). Chronic schizophrenia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-schizophrenia. Accessed 2026-06-10.

Chronic schizophrenia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing